查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984115

急性綜合症檢測市場：按產品類型、症候群檢測組合、技術、應用和最終用戶分類－2026-2032年全球市場預測

Acute Care Syndromic Testing Market by Product Type, Syndromic Panel, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，急性症候群檢測市場價值將達到 74.4 億美元，到 2026 年將成長至 84 億美元，到 2032 年將達到 181.4 億美元，年複合成長率為 13.58%。

主要市場統計數據
基準年 2025 74.4億美元
預計年份：2026年 84億美元
預測年份 2032 181.4億美元
複合年成長率 (%) 13.58%

簡要介紹急性症候群檢測的模式轉移：說明臨床整合、診斷速度和系統彈性。

在技​​術進步、臨床工作流程變革以及對診斷速度和準確性日益成長的期望的推動下，急性護理中的症候群檢測領域正經歷著快速且永續的發展。能夠同時檢測多種病原體的症候群檢測在急診醫學和醫院環境中正變得越來越普遍，因為在這些環境中，時間緊迫的決策會對患者的預後產生重大影響。隨著臨床團隊努力縮短診斷時間並減少對經驗性治療的依賴，能夠與臨床工作流程無縫整合的診斷平台正從概念驗證驗證階段邁向實際應用階段。

技術、監管和醫療保健服務方面的變革正在重塑症候群檢測的途徑，並加速醫療保健機構中照護現場診斷的普及。

一系列變革正在重新定義急診護理環境中綜合症檢測的開發、實施和維護。高倍率檢測、整合式檢體到結果平台以及先進的資料管理功能等技術創新正在降低快速診斷的門檻。這些技術與改進的檢測設計相輔相成，在保持分析靈敏度和特異性的同時，擴大了病原體的檢測範圍，從而使臨床應用從傳統的呼吸道疾病檢測擴展到神經系統、消化器官系統和性行為感染感染等領域。

評估 2025 年美國關稅調整對供應鏈、醫療設備採購、製造獎勵和臨床營運的多方面影響。

2025年美國關稅政策的調整為參與綜合症檢測的製造商、經銷商和醫療保健機構帶來了新的挑戰。由於進口成本上升和前置作業時間不不確定性增加，原本以即時庫存管理為最佳化策略的供應鏈被迫重新評估其籌資策略。為此，許多醫療設備和試劑供應商加快了供應商網路的多元化，並探索區域性生產和組裝方案，以降低進口價格波動帶來的風險。

深入的細分分析揭示了急性護理環境中面板採用模式和採購決策如何受到面板類型、產品類型、最終用戶、技術和應用的影響。

精準理解市場區隔動態對於掌握需求集中區域以及採購決策的變化至關重要。在考慮使用針對特定症候群的檢測組合時，由於神經系統感染的嚴重性，中樞神經系統疾病（包括腦炎和腦膜炎亞型）的檢測組合優先考慮高分析靈敏度和快速出結果。消化器官系統感染疾病檢測組合（區分細菌、寄生蟲和病毒病原體）需要強大的多重檢測能力和檢體通用性。呼吸系統疾病檢測組合（分為細菌、複雜病原體和病毒病原體）必須在廣泛的檢測覆蓋範圍和處理能力之間取得平衡，以應對季節性需求高峰。性行為感染檢測組合（針對披衣菌感染、淋病和皰疹）需要能夠處理多種檢體類型的高特異性檢測方法。

影響症候群檢測計畫實施和支持的區域趨勢和戰略考慮因素，包括美洲、歐洲、中東和非洲以及亞太地區。

區域趨勢對症候群檢測項目的部署策略、監管協調和支援基礎設施有顯著影響。在美洲，擴大照護現場和與電子健康記錄系統整合的獎勵正在推動醫院和門診診所的部署，而區域供應鏈中心和生產能力則支援快速補貨。在歐洲、中東和非洲，不同的法規結構和報銷環境需要差異化的商業化策略以及客製化的服務模式，以適應檢查室整合和集中化的不同趨勢。在亞太地區，產能的快速擴張、本地生產投資以及對公共衛生監測的高度重視正在加速高通量和分散式平台的部署。

競爭格局和公司層面的策略如何影響急性症候群檢測生態系統中的創新、夥伴關係和商業化。

在症候群檢測生態系統中，企業策略正沿著多個維度不斷演進，包括平台差異化、耗材垂直整合以及與檢查室網路和醫療保健系統的策略合作。製造商致力於提供端到端解決方案，以最大限度地減少工作量、降低故障點，並實現與實驗室資訊系統和電子健康記錄的無縫整合。同時，各公司也投資於能夠支援持續收入的耗材產品組合，並致力於設計模組化設備，以確保客戶不會受到設備過時的影響。

為產業領導者提供切實可行的策略建議，以最佳化供應鏈韌性、加速臨床部署，並使經營模式與醫療保健優先事項保持一致。

尋求獲得永續競爭優勢的行業領導者應優先考慮一系列綜合舉措，以協調技術、供應鏈、臨床應用和商業模式。首先，投資於平台互通性和開放資料標準能夠加速臨床整合，並支援下游分析以展現價值。其次，在製定本地分銷應急計劃的同時，實現製造和物流合作夥伴的多元化，可以最大限度地減少貿易中斷和海關程序波動對營運的影響。第三，透過真實世界數據 (REW) 研究和以管理為重點的試點項目，將臨床證據的生成融入商業部署，可以加速技術應用，並加強與保險公司的對話。

採用綜合調查方法，結合一手訪談、二手文獻、資料檢驗和檢驗，確保嚴謹而實用的見解。

本報告所採用的分析方法結合了結構化的初步研究、全面的二手文獻綜述和嚴謹的資料三角驗證，從而確保了結論的可靠性和可操作性。初步研究包括對臨床實驗室負責人、採購經理、醫院管理人員和技術開發人員進行深入訪談，以了解實際運作和決策標準。二級資訊來源包括同行評審的臨床研究、監管指南、技術白皮書和公開的產品文​​檔，用於闡明性能特徵和檢驗標準。

為了支持症候群檢測中的經營團隊決策，我們整合了相關結論，提取了對臨床護理、營運和產業策略的關鍵見解。

總之，在急診護理中，症候群檢測正從一項新興功能轉變為快速臨床決策、感染控制和公共衛生監測的營運基礎。科技的成熟、醫療服務模式的變革以及政策環境的演變正在推動其更廣泛的應用，而供應鍊和貿易趨勢則凸顯了韌性和多元化籌資策略的重要性。細分市場分析表明，不同應用領域的臨床優先事項各不相同。神經系統急症需要快速且高靈敏度的檢測，而呼吸系統疾病的激增則需要可擴展的檢測能力和靈活的檢測組合，這就需要採用個人化的採購和檢驗方法來滿足這些需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：急性症候群檢測市場：依產品類型分類

  • 裝置
    • 工作檯面
    • 照護端
  • 試劑盒和試劑
    • 墨水匣
    • 連接複用檢測套組
    • 試劑
  • 軟體服務
    • 資料管理
    • 服務合約

第9章：急性症候群檢測市場－依症候群和檢測項目分類

  • 中樞神經系統
    • 腦炎
    • 腦膜炎
  • 消化器官系統
    • 細菌
    • 寄生蟲
    • 病毒性的
  • 呼吸系統
    • 細菌
    • 合成的
    • 病毒性的
  • 性行為感染傳染病
    • 披衣菌感染和淋病
    • 皰疹

第10章：急性症候群檢測市場：依技術分類

  • 質譜分析
  • 微陣列
  • 多重PCR
  • NGS
  • QPCR

第11章：急性症候群檢測市場：依應用領域分類

  • 鑑別診斷
  • 流行病學
  • 集體爆發調查
  • 研究
  • 監視

第12章：急性症候群檢測市場：依最終用戶分類

  • 學術研究機構
  • 醫院
  • 公共衛生檢測實驗室
  • 標準檢驗組織

第13章：急性症候群檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：急性症候群檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：急性症候群檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國急性症候群檢測市場

第17章：中國急性病症檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Applied BioCode, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • BIOHM Health LLC
  • bioMerieux SA
  • Curetis GmbH by OpGen, Inc
  • CVS Health
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Genetic Signatures Ltd.
  • Hologic Inc.
  • Luminex Corporation
  • Microbiologics, Inc.
  • Pfizer, Inc.
  • QIAGEN NV
  • QuantuMDx Group Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Werfen
Product Code: MRR-5A3042B3D68E

The Acute Care Syndromic Testing Market was valued at USD 7.44 billion in 2025 and is projected to grow to USD 8.40 billion in 2026, with a CAGR of 13.58%, reaching USD 18.14 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.44 billion
Estimated Year [2026] USD 8.40 billion
Forecast Year [2032] USD 18.14 billion
CAGR (%) 13.58%

A concise introduction to the shifting paradigm in acute care syndromic testing, highlighting clinical integration, diagnostic speed, and system resilience

The landscape of acute care syndromic testing is experiencing a rapid and sustained evolution driven by technological advances, shifting clinical workflows, and heightened expectations for diagnostic speed and precision. Syndromic testing, which enables simultaneous detection of multiple pathogen classes, is increasingly embedded into urgent care and hospital settings where time-sensitive decisions can materially affect patient outcomes. As clinical teams seek to shorten diagnostic windows and reduce empiric therapy reliance, diagnostic platforms that integrate seamlessly with care pathways are moving from proof-of-concept to operational necessity.

Moreover, the interplay between laboratory infrastructure and point-of-care capabilities is reshaping procurement priorities. Healthcare administrators are balancing the need for high-throughput centralized testing with decentralized solutions that deliver actionable results close to the bedside. In parallel, public health authorities and infection prevention teams are leveraging syndromic data to support surveillance and outbreak response, further emphasizing the role of diagnostics in broader population health strategies. Consequently, stakeholders across clinical, operational, and commercial functions must align around real-world performance, interoperability, and the ability to demonstrate clinical utility within constrained budgets.

Transformative technological, regulatory, and care-delivery shifts reshaping syndromic testing pathways and accelerating point-of-care diagnostics adoption across institutions

Transformative shifts are converging to redefine how syndromic testing is developed, adopted, and sustained in acute care settings. Technological innovations such as highly multiplexed assays, integrated sample-to-answer platforms, and advanced data management capabilities are lowering barriers to rapid diagnosis. These technologies are complemented by improvements in assay design that increase pathogen breadth while preserving analytical sensitivity and specificity, which in turn expands clinical use cases beyond traditional respiratory panels into neurological, gastrointestinal, and sexually transmitted infection applications.

Concurrently, care-delivery models are adapting; emergency departments, intensive care units, and outpatient urgent care centers are demanding faster turnarounds and simplified workflows that reduce dependency on specialized laboratory staff. Regulatory landscapes and reimbursement frameworks are also evolving, encouraging faster adoption when clinical value can be demonstrated through outcomes, antibiotic stewardship, and reduced length of stay. Finally, digital connectivity and analytics are enabling near-real-time aggregation of syndromic results, creating opportunities for improved institutional surveillance and cross-institutional public health signal detection. Taken together, these shifts are accelerating the translation of syndromic testing from niche diagnostic aid to an essential element of acute care management.

Assessing the multifaceted consequences of United States tariff adjustments in 2025 on supply chains, device sourcing, manufacturing incentives, and clinical operations

Adjustments to tariff policies in the United States during 2025 introduced renewed considerations for manufacturers, distributors, and healthcare providers involved with syndromic testing. Supply chains that had been optimized for just-in-time inventory were forced to re-evaluate sourcing strategies as import costs and lead-time uncertainty increased. In response, many device and reagent suppliers accelerated diversification of vendor networks and explored regional manufacturing and assembly options to mitigate exposure to import volatility.

Consequently, procurement teams in hospitals and reference laboratories instituted more stringent supplier risk assessments and prioritized long-term supply agreements that provided greater transparency around capacity and contingency planning. For platform manufacturers, the tariff environment prompted reassessment of pricing structures and total cost of ownership models that account for logistics, customs delays, and inventory carrying costs. Over time, these adjustments influenced product roadmaps and capital allocation decisions, encouraging investments in modular designs and interchangeable consumables that reduce dependency on single-source components.

Importantly, clinical operations experienced transitional friction as lead-time variability affected kit availability for high-demand panels. In response, laboratories expanded validation of alternative assays and intensified collaboration with clinical stakeholders to prioritize testing based on acuity and infection control imperatives. Through these adaptations, the sector demonstrated resilience, but the tariff-induced disruptions underscored the strategic importance of supply chain transparency, manufacturing agility, and proactive stakeholder communication.

Insightful segmentation analysis revealing how panels, product types, end users, technologies, and applications drive adoption patterns and procurement decisions in acute care

A nuanced understanding of segmentation dynamics is essential to appreciate where demand will concentrate and how procurement choices will evolve. When testing is considered by syndromic panel, the central nervous system category, with its encephalitis and meningitis subgroups, prioritizes high analytical sensitivity and rapid turnaround due to the critical nature of neurological infections; gastrointestinal panels that distinguish bacterial, parasitic, and viral etiologies demand robust multiplex capability and specimen versatility; respiratory panels categorized across bacterial, combined, and viral targets must balance breadth with throughput to serve seasonal surges; and sexually transmitted infection panels that profile chlamydia, gonorrhea, and herpes require assays optimized for diverse specimen types and high specificity.

From a product-type perspective, instruments-ranging from benchtop analyzers to point-of-care devices-drive capital planning and lab footprint decisions, while kits and reagents including cartridges, multiplex assay kits, and standalone reagents underpin recurring revenue and supply continuity considerations; software and services focused on data management and service contracts are increasingly decisive for long-term total cost and operational efficiency. End-user segmentation clarifies adoption pathways: academic research institutes prioritize assay flexibility and depth for translational work, hospitals require validated workflows and rapid clinical reporting, public health laboratories emphasize surveillance compatibility and high-throughput capacity, and reference laboratories focus on scale and assay multiplexing to serve broad client networks. Technology choices also shape strategy: options such as mass spectrometry, microarray, multiplex PCR, next-generation sequencing, and qPCR each present distinct trade-offs in throughput, breadth, and turn-around time. Finally, applications including differential diagnosis, epidemiology, outbreak investigation, research, and surveillance determine performance requirements and the degree of integration with clinical and public health information systems. Collectively, these segmentation axes inform procurement prioritization, validation strategies, and partnership models across stakeholders.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence deployment and support of syndromic testing programs

Regional dynamics materially influence deployment strategies, regulatory alignment, and support infrastructures for syndromic testing programs. In the Americas, incentives for point-of-care expansion and integrated electronic health record connectivity are shaping hospital and outpatient adoption, while regional supply chain hubs and manufacturing capacity support responsive replenishment. Across Europe, the Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement environments necessitate differentiated commercialization approaches, as well as tailored service models that account for variable laboratory consolidation and centralization trends. In the Asia-Pacific region, rapid capacity expansion, localized manufacturing investments, and strong public health surveillance priorities have accelerated adoption of both high-throughput and decentralized platforms.

These regional distinctions affect not only where technologies are adopted but how companies structure market entry and post-sale support. For instance, service contracts and local technical support are critical in regions with limited on-site technical expertise, whereas software interoperability and data-sharing standards are prioritized in systems with advanced digital health infrastructures. Moreover, procurement cycles and capital allocation differ across regions, influencing the pace of roll-out for new panels and platform upgrades. Understanding these geographic nuances enables planners to align distribution strategies, local partnerships, and training programs to regional expectations and operational realities.

Competitive landscape and company-level strategies shaping innovation, partnerships, and commercialization in the acute care syndromic testing ecosystem

Corporate strategies within the syndromic testing ecosystem are evolving along multiple vectors, including platform differentiation, vertical integration of consumables, and strategic partnerships with laboratory networks and health systems. Manufacturers focus on delivering end-to-end solutions that minimize hands-on time, reduce failure points, and provide seamless connectivity to laboratory information systems and electronic medical records. At the same time, firms are investing in consumable portfolios that support recurring revenue while designing instruments with modularity to protect customers against obsolescence.

Partnerships and consortium models are emerging as a way to accelerate market penetration and validate clinical utility across diverse care settings. Companies are increasingly collaborating with academic centers for clinical validation studies and with public health agencies to align reporting formats and surveillance use cases. Competitive dynamics are also influenced by service models, as rapid-response technical support and managed inventory programs become differentiators in procurement decisions. Overall, the marketplace favors organizations that can combine robust analytical performance with strong post-sale support, clear integration pathways, and flexible commercial terms that accommodate varied end-user needs.

Actionable strategic recommendations for industry leaders to optimize supply resilience, accelerate clinical adoption, and align commercial models with healthcare priorities

Industry leaders seeking to secure sustainable advantage should prioritize a set of integrated actions that address technology, supply chain, clinical adoption, and commercial alignment. First, investing in platform interoperability and open data standards will accelerate clinical integration and enable downstream analytics that demonstrate value. Second, diversifying manufacturing and logistics partners while building regional distribution contingencies will minimize the operational impact of trade disruptions and customs variability. Third, embedding clinical evidence generation into commercial rollouts-through real-world evidence studies and stewardship-focused pilots-will strengthen adoption and payer conversations.

Additionally, executives should consider modular pricing and service models that lower barriers to initial deployment and offer predictable total cost of ownership over time. Strengthening technical support and training programs will reduce implementation friction and improve clinician confidence in decentralized settings. Finally, cultivating strategic partnerships with public health institutions and reference networks can expand surveillance reach while creating shared validation pathways. By aligning product roadmaps, commercial models, and operational resilience initiatives, industry leaders can accelerate adoption while mitigating near-term market volatility.

Comprehensive research methodology integrating primary interviews, secondary literature, data triangulation, and validation to ensure rigorous and actionable insights

The analytical approach underpinning this report combined structured primary research, exhaustive secondary literature review, and rigorous data triangulation to ensure reliable and actionable findings. Primary research included in-depth interviews with clinical laboratory directors, procurement leads, hospital administrators, and technology developers to capture operational realities and decision-making criteria. Secondary sources comprised peer-reviewed clinical studies, regulatory guidance, technology white papers, and publicly available product documentation to contextualize performance characteristics and validation standards.

Data integration involved cross-checking interview insights against documented validation data and regulatory filings, enabling identification of consistent themes and divergence points. The methodology incorporated scenario analysis to explore supply chain sensitivities and adoption pathways under varying clinical and policy conditions. Quality assurance steps included multiple rounds of expert review and internal consistency checks to ensure that conclusions were robust and that limitations were transparently acknowledged. Where relevant, caveats around generalizability and regional applicability were stated to help readers interpret findings within their operational context.

Concluding synthesis that distills key implications for clinical care, operations, and industry strategy to inform executive decision-making in syndromic testing

In summary, syndromic testing in acute care is transitioning from emerging capability to an operational cornerstone of rapid clinical decision-making, infection control, and public health surveillance. Technological maturation, shifting care delivery models, and evolving policy contexts are collectively driving broader adoption, while supply chain and trade dynamics highlight the importance of resilience and diverse sourcing strategies. Segmentation analyses make clear that clinical priorities differ by application area-neurological emergencies require rapid, high-sensitivity assays while respiratory surges demand scalable throughput and flexible panel composition-necessitating tailored procurement and validation approaches.

Looking forward, stakeholders who combine technological interoperability, robust service models, and evidence-driven adoption programs will be best positioned to capture clinical and operational benefits. Strategic investments in localized manufacturing, flexible commercial offerings, and partnerships with public health and academic institutions will further enhance system preparedness. Ultimately, the organizations that align product design with real-world workflows and demonstrate measurable clinical impact will lead the transition toward more responsive, data-informed acute care diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Care Syndromic Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop
    • 8.1.2. Point Of Care
  • 8.2. Kits Reagents
    • 8.2.1. Cartridges
    • 8.2.2. Multiplex Assay Kits
    • 8.2.3. Reagents
  • 8.3. Software Services
    • 8.3.1. Data Management
    • 8.3.2. Service Contracts

9. Acute Care Syndromic Testing Market, by Syndromic Panel

  • 9.1. Central Nervous System
    • 9.1.1. Encephalitis
    • 9.1.2. Meningitis
  • 9.2. Gastrointestinal
    • 9.2.1. Bacterial
    • 9.2.2. Parasitic
    • 9.2.3. Viral
  • 9.3. Respiratory
    • 9.3.1. Bacterial
    • 9.3.2. Combined
    • 9.3.3. Viral
  • 9.4. Sexually Transmitted Infection
    • 9.4.1. Chlamydia Gonorrhea
    • 9.4.2. Herpes

10. Acute Care Syndromic Testing Market, by Technology

  • 10.1. Mass Spectrometry
  • 10.2. Microarray
  • 10.3. Multiplex Pcr
  • 10.4. Ngs
  • 10.5. Qpcr

11. Acute Care Syndromic Testing Market, by Application

  • 11.1. Differential Diagnosis
  • 11.2. Epidemiology
  • 11.3. Outbreak Investigation
  • 11.4. Research
  • 11.5. Surveillance

12. Acute Care Syndromic Testing Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Hospitals
  • 12.3. Public Health Laboratories
  • 12.4. Reference Laboratories

13. Acute Care Syndromic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Care Syndromic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Care Syndromic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Acute Care Syndromic Testing Market

17. China Acute Care Syndromic Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Applied BioCode, Inc.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Biocartis NV
  • 18.10. BIOHM Health LLC
  • 18.11. bioMerieux SA
  • 18.12. Curetis GmbH b y OpGen, Inc
  • 18.13. CVS Health
  • 18.14. Danaher Corporation
  • 18.15. DiaSorin S.p.A
  • 18.16. Eurofins Scientific SE
  • 18.17. F. Hoffmann-La Roche Ltd
  • 18.18. Genetic Signatures Ltd.
  • 18.19. Hologic Inc.
  • 18.20. Luminex Corporation
  • 18.21. Microbiologics, Inc.
  • 18.22. Pfizer, Inc.
  • 18.23. QIAGEN N.V.
  • 18.24. QuantuMDx Group Ltd.
  • 18.25. Seegene Inc.
  • 18.26. Siemens Healthineers AG
  • 18.27. Sysmex Corporation
  • 18.28. Thermo Fisher Scientific Inc.
  • 18.29. Werfen

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SERVICE CONTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ENCEPHALITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CHLAMYDIA GONORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY DIFFERENTIAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY OUTBREAK INVESTIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SYNDROMIC PANEL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 293. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 294. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 295. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION, 2018-2032 (USD MILLION)
  • TABLE 296. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. G7 ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO ACUTE CARE SYNDROMIC TESTING MARKET SIZE, BY KITS REAGENTS, 2018-203